Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A, Kutzera J, Geenen JJ, Pluim D, Hofland I, Sanders J, Lopez-Yurda M, Beijnen JH, Huitema ADR, Witteveen PO, Steeghs N, van Haaften G, van Vugt MATM, de Ridder J, Opdam FL. Embaby A, et al. Among authors: opdam fl. Gynecol Oncol. 2023 Jul;174:239-246. doi: 10.1016/j.ygyno.2023.05.063. Epub 2023 May 24. Gynecol Oncol. 2023. PMID: 37236033 Clinical Trial.
Breath tests to phenotype drug disposition in oncology.
Opdam FL, Modak AS, Gelderblom H, Guchelaar HJ. Opdam FL, et al. Clin Pharmacokinet. 2013 Nov;52(11):919-26. doi: 10.1007/s40262-013-0099-9. Clin Pharmacokinet. 2013. PMID: 23868281 Review.
Lapatinib for advanced or metastatic breast cancer.
Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Opdam FL, et al. Oncologist. 2012;17(4):536-42. doi: 10.1634/theoncologist.2011-0461. Epub 2012 Apr 3. Oncologist. 2012. PMID: 22477724 Free PMC article. Review.
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, de Vos FYFL, Lolkema MPJK, Devriese LA, Opdam FL, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. van Geel RMJM, et al. Among authors: opdam fl. Br J Cancer. 2020 Apr;122(8):1166-1174. doi: 10.1038/s41416-020-0776-z. Epub 2020 Mar 9. Br J Cancer. 2020. PMID: 32147669 Free PMC article. Clinical Trial.
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Huijberts SCFA, van Geel RMJM, van Brummelen EMJ, Opdam FL, Marchetti S, Steeghs N, Pulleman S, Thijssen B, Rosing H, Monkhorst K, Huitema ADR, Beijnen JH, Bernards R, Schellens JHM. Huijberts SCFA, et al. Among authors: opdam fl. Cancer Chemother Pharmacol. 2020 May;85(5):917-930. doi: 10.1007/s00280-020-04066-4. Epub 2020 Apr 9. Cancer Chemother Pharmacol. 2020. PMID: 32274564 Clinical Trial.
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
van Brummelen EMJ, Huijberts S, van Herpen C, Desar I, Opdam F, van Geel R, Marchetti S, Steeghs N, Monkhorst K, Thijssen B, Rosing H, Huitema A, Beijnen J, Bernards R, Schellens J. van Brummelen EMJ, et al. Oncologist. 2021 Apr;26(4):290-e545. doi: 10.1002/onco.13631. Epub 2020 Dec 29. Oncologist. 2021. PMID: 33296125 Free PMC article. Clinical Trial.
39 results